| Name | Title | Contact Details |
|---|
Abbott Diabetes Care is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PCI Pharma Services is a global leader in Contract Development and Manufacturing Organization (CDMO) services, offering integrated solutions for drug development, manufacturing, and packaging. The company focuses on innovation and patient-centric approaches, supporting pharmaceutical and biopharmaceutical companies at various stages of drug development and commercialization. With 30 Good Manufacturing Practice (GMP) facilities across seven countries, PCI employs over 4,300 people dedicated to delivering life-changing therapies. The company provides a comprehensive range of services, including drug development and manufacturing for various dosage forms, advanced drug delivery systems, and complex packaging solutions. PCI also manages storage, distribution, and logistics to support the pharmaceutical supply chain and offers clinical trial supply chain management. Committed to growth, PCI has made significant investments, including a $100 million expansion in New England to enhance its global capacity and capabilities.
Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare`s platform combines a proprietary, high throughput, CRISPR‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics.
Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology`s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn`t tied to one form of drug or any singular approach to treating cancer. By keeping an open mind about what is possible, we believe we will achieve the greatest results for patients everywhere.